4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV

Highlights are presented from this annual workshop, which was devoted to the investigation of adverse effects associated with antiretroviral therapy for HIV infection. Topics covered included the lipodystrophy syndrome, which encompasses body composition changes (subcutaneous fat wasting, visceral fat accumulation) and metabolic abnormalities (insulin resistance and dyslipidaemia). The relevance of HIV protease inhibitor-induced metabolic abnormalities to cardiovascular disease is discussed. Research in the areas of hyperlactataemia, abacavir hypersensitivity, and bone mineral density in the context of HIV infection is also briefly reviewed.

[1]  B. Gazzard,et al.  Matched case–control study to evaluate risk factors for hyperlactataemia in HIV patients on antiretroviral therapy , 2003, HIV medicine.

[2]  I. Weller,et al.  Lactic acidosis in HIV infected patients: a systematic review of published cases , 2002, Sexually transmitted infections.

[3]  W. Powderly,et al.  Switching effective antiretroviral therapy: a review. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  K. Frayn.  Insulin Resistance, Impaired Postprandial Lipid Metabolism and Abdominal Obesity , 2002, Medical Principles and Practice.

[5]  J. J. de la Cruz,et al.  Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. , 2002, AIDS.

[6]  Amalio Telenti,et al.  Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. , 2002, AIDS.

[7]  T. Buchanan,et al.  Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  D. Cooper,et al.  Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. , 2002, JAMA.

[9]  Clive E. Bowman,et al.  Genetic variations in HLA-B region and hypersensitivity reactions to abacavir , 2002, The Lancet.

[10]  M. Schambelan,et al.  Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: A randomized, placebo-controlled study , 2002, AIDS.

[11]  C. Moore,et al.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.

[12]  P. Morlat,et al.  Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  W. Dietz,et al.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.

[14]  A. Liappis,et al.  Antiretroviral therapy-induced changes in lipoprotein subclass phenotype: comparison of protease inhibitor and non-nucleoside reverse transcriptase inhibitor regimens , 2002 .

[15]  G. Guaraldi,et al.  Physician-patient concordance on lipodystrophy severity , 2002 .

[16]  B Clotet,et al.  Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile , 2001, AIDS.

[17]  P. McBride,et al.  Use of Human Immunodeficiency Virus-1 Protease Inhibitors Is Associated With Atherogenic Lipoprotein Changes and Endothelial Dysfunction , 2001, Circulation.

[18]  M. John,et al.  Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir , 2001, AIDS.

[19]  W. Wilkison,et al.  Adipogenic potential of human adipose derived stromal cells from multiple donors is heterogeneous , 2001, Journal of cellular biochemistry.

[20]  M. John,et al.  Antiretroviral Therapy and the Lipodystrophy Syndrome , 2001, Antiviral therapy.

[21]  R. Krauss,et al.  Atherogenicity of triglyceride-rich lipoproteins. , 1998, The American journal of cardiology.

[22]  K. Feingold,et al.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. , 1992, The Journal of clinical endocrinology and metabolism.